Genetic Technologies surges 40% on back of agreement
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Provider of world-leading genetic risk assessment test products Genetic Technologies Limited (ASX:GTG), has signed a 3-year Collaboration Agreement with TGen.
This is an extremely important development for the company, and one that has triggered a sharp share price increase on Monday morning.
In the first half hour of trading the company’s shares were up as much as 40%.
TGen, an affiliate of City of Hope in Duarte, California, is an Arizona-based, non-profit biomedical research institute dedicated to conducting ground-breaking research with life-changing results.
Physicians and scientists at TGen work to understand the genetic components of both common and complex diseases, including cancer, neurological disorders, infectious disease, and rare childhood disorders.
They are also focused on the translation of clinically useful genomics discoveries into the clinic.
In pursuit of clinical evidence for GTG’s test
The collaboration agreement will see Genetic Technologies and TGen cooperating in the design feasibility analysis of clinical research studies to support a clinical application of the former’s polygenic risk tests.
The initial focus of the studies will be the clinical utility of the GeneType Breast and Colorectal Cancer risk tests developed by Genetic Technologies.
This aims to demonstrate the value of these tests for clinicians when assessing individual risk profiles.
Genetic Technologies and TGen will also identify appropriate clinical partners to participate in the studies.
Once completed, it is expected that these studies will provide strong clinical evidence to support the use of the polygenic risk tests as an important routine tool in predicting individual disease risk.
They can then assist clinicians to develop individual risk management programmes for improved prevention and treatment of these diseases.
While the terms of the agreement are confidential, key features include that GTG and TGen will cooperate in the design and conduct of clinical utility studies for a suite of polygenic risk tests for common diseases to be developed and made available in the US market.
The clinical utility studies are intended to translate GeneType tests into daily clinical use.
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
